EGFR and neoplasm: The analysis of resistance mechanisms by NGS of tumor tissue and ctDNA revealed a not-negligible activity of the combination both in the EGFR-MET-mediated subgroup (RR = 47%) and in the group of patients with unknown resistance mechanisms (RR = 50%), while no responses were recorded in case of EGFR-MET-independent resistance.